Anke Hildebrandt

Anke Hildebrandt is an accomplished regulatory affairs professional with extensive experience in the pharmaceutical industry. Currently serving as Executive Director of Regulatory Affairs EU at Dyne Therapeutics since April 2025, Anke has previously held senior roles including Executive Director of Regulatory Affairs at HOOKIPA Pharma Inc. and Director of Regulatory Affairs at Takeda, where responsibilities included the development of regulatory strategies and management of submissions for hematology products. Anke's career spans several notable companies including Shire, Baxalta, Merck, Astellas Europe, Sandoz, Sanofi, and GSK, demonstrating a consistent commitment to regulatory excellence and cross-functional leadership. Anke holds a Doctorate in Pharmacology and an MBA-like post-graduate degree from Technische Universität Wien, along with a Pharmacy degree from the University of Vienna.